Pierre Meulien
Executive Director,
Innovative Medicines Initiative
Pierre Meulien joined IMI as Executive Director in September 2015.
Prior to that Pierre Meulien was President and Chief Executive Officer (CEO) of Genome Canada, a not-for-profit organisation that connects ideas and people across public and private sectors to find new uses for genomics and invests in large-scale science and technology to fuel innovation in key sectors, including health. While at Genome Canada, he succeeded in securing significant funding from the Government of Canada and leveraged further funds through partnerships. He also developed the Genomics Innovation Network to keep Canada at the cutting edge of genomics-based technologies.
Before joining Genome Canada in 2010, he served as Chief Scientific Officer for Genome British Columbia, where he promoted the organisation’s scientific strategy. Prior to that, he was founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland) which linked the three medical schools and six teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research.
Pierre Meulien also has experience of working in industry, having worked at Aventis Pasteur in Canada and France, and at French biotechnology company Transgene. He has a PhD in molecular biology from the University of Edinburgh and worked as a post-doctoral researcher at the Institut Pasteur in Paris.